Skip to content
SB-431542

Structure via PubChem · Public domain (PubChem)

EntityQ7388913· pop 6· linked from 88 articles

Also known as compound 14, SB431542, 4-(4-(1,3-Benzodioxole-5-yl)-5-(2-pyridyl)-1H-imidazole-2-yl)benzamide

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7. However, it is not an inhibitor of anaplastic lymphoma kinase (which are commonly known as ALK inhibitors).

Chemical data

Formula
C22H16N4O3
Molecular weight
384.4 g/mol
IUPAC name
4-[4-(1,3-benzodioxol-5-yl)-5-pyridin-2-yl-1H-imidazol-2-yl]benzamide
SMILES
C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
InChIKey
FHYUGAJXYORMHI-UHFFFAOYSA-N
XLogP
2.7
Polar surface area
103 Ų
H-bond donors
2
H-bond acceptors
5
Formal charge
0

via PubChem

Drug data · ChEMBL

Molecule type
Small molecule

via ChEMBL · EBI

Wikidata facts

Mass
384.122
Show 3 more facts
chemical formula
C₂₂H₁₆N₄O₃
found in taxon
Penicillium
canonical SMILES
C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

2 sections
Contents
  • In-vitro studies
  • References

SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7. However, it is not an inhibitor of anaplastic lymphoma kinase (which are commonly known as ALK inhibitors).

==In-vitro studies== While SB-431542 has not proved directly useful for any clinical application, it is used for several applications in molecular biology. It suppresses the TGF-beta-induced proliferation of osteosarcoma cells in humans. SB431542 can also be used in combination with LDN193189, CHIR99021 and DAPT to transform astrocytes into neurons. It is also commonly used for immunological studies, for instance as a TGF-β inhibitor to facilitate the generation of dendritic cells from peripheral blood monocytes.

Excerpted from Wikipedia’s “SB-431542” article, available under the CC BY-SA 4.0 licence.

Available in 6 languages

via Wikidata sitelinks · CC0